Olaratumab to Be Withdrawn From Market Access Program Planned in Soft Tissue Sarcoma

Olaratumab to Be Withdrawn From Market, Access Program Planned in Soft Tissue Sarcoma

Eli Lilly and Company has announced that it is withdrawing its PDGFRα antagonist olaratumab from the market for the treatment of patients with advanced soft tissue sarcoma.

More From BioPortfolio on "Olaratumab to Be Withdrawn From Market, Access Program Planned in Soft Tissue Sarcoma"